About Aerpio


Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.

Our lead product candidate, AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. AKB-9778 is currently in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR), a disease that affects millions of people across the globe.

Innovative approach: Targeting the Tie2 pathway to stabilize vasculature in multiple retinopathies

Vascular stabilization by activation of the Tie2 pathway is of high interest in multiple indications, including several retinopathies. Aerpio is a leader in this area and is developing first in class treatments for ocular diseases based on novel therapeutics targeting vascular endothelial-protein tyrosine phosphatase (VE-PTP), a key negative regulator of the Tie2 pathway in vascular endothelial cells. 

Click here to learn more about Tie2

Click here to learn more about VE-PTP

A non-intravitreal treatment option for early diabetic eye disease

Our lead candidate, AKB-9778, is a first-in-class small molecule activator of the Tie2 pathway. AKB-9778 works by inhibiting activity of VE-PTP.

In contrast to current therapies, which require repeated injections into the eye, AKB-9778 is being developed as a patient self-administered, subcutaneous injection, similar to insulin. A randomized, multi-center, placebo-controlled Phase 2b study (TIME-2b) of AKB-9778 in patients with NPDR is currently on-going.  

Click here to learn more about AKB-9778

Click here to learn more about TIME-2b 

Click here to learn more about NPDR

Building a strong pipeline focused on the Tie2 pathway

The second program in development builds on our innovative approach to targeting the Tie2 pathway. ARP-1536 is a humanized monoclonal antibody that works by binding the extracellular domain of VE-PTP inhibiting its ability to interact with the Tie2 receptor. This prevents the inactivation of Tie2 and promotes vascular stability.

ARP-1536 is in pre-clinical development. We plan on developing ARP-1536 in combination with anti-VEGF therapy for the treatment of  wet age-related macular degeneration (AMD) and  diabetic macular edema (DME)

Click here to learn more about ARP-1536

Click here to learn more about wet AMD and DME

Development beyond ophthalmology

AKB-4924 is a unique small molecule inhibitor of prolyl-hydroxylase domain enzymes (PHDs). PHDs are key regulators of hypoxia inducible factor-1 alpha (HIF-1 alpha) which, when dysregulated, has been shown to exacerbate inflammation and disrupt intestinal epithelial barrier function.

By inhibiting PHDs, AKB-4924 stabilizes HIF-1 alpha leading to resolution of inflammation and restoration of epithelial barrier function. AKB-4924 is in Phase 1 clinical development and we plan on developing it as a once-daily, oral treatment for inflammatory bowel disease (IBD).

Click here to learn more about AKB-4924

Click here to learn more about IBD